UNSPSC 51181579: Empagliflozin

Empagliflozin is a medication used together with diet and exercise to treat type 2 diabetes. It can be prescribed instead of metformin and has benefits over sulfonylureas.

UNSPSC 51181579 Empagliflozin, a Commodity code, shows no recent state and local procurement activity. The recent opportunities block contains notices for nursing homes, medical equipment rental, pharmaceuticals procurement through cooperative purchasing, and trade shows and vendor forums—none of which involve empagliflozin, a diabetes medication in the SGLT2-inhibitor class. One entry (Seminole County's Naloxone procurement) involves pharmaceutical products but addresses opioid emergency response, not diabetes treatment. The MMCAP cooperative procurement for generic multi-source pharmaceuticals and OTC products, while substantial in scope and reaching state and local buyers across Oregon and Minnesota, does not name empagliflozin among eligible drug classes. The remaining records are networking events, vendor forums, or administrative notices unrelated to pharmaceutical procurement. State and local governments do not appear to be soliciting empagliflozin systematically under this code at present; if procurement occurs, it likely flows through health plan, correctional facility, or hospital purchasing channels and may be coded or titled differently in procurement systems.

Activity under this code does not support meaningful business development signals at this time. Monitor for future solicitations from county health systems, state Medicaid agencies, and cooperative purchasing vehicles covering chronic-disease pharmacy benefit programs, where SGLT2 inhibitors would be relevant procurement items. The absence of recent activity under this specific code does not indicate lack of government demand for the drug itself—only that state and local procurement systems are not currently surfacing opportunities classified as 51181579 Empagliflozin.